HANGZHOU, China--(BUSINESS WIRE)--Hangzhou Qihan Biotech Co., Ltd. ('Qihan' or 'Qihan Biotech' or 'the Company'), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced its groundbreaking research titled 'Testing Multiplexed anti-ASFV CRISPR-Cas9 in Reducing African Swine Fever Virus' in Microbiology Spectrum, an academic journal of the American Society for Microbiology.

中国杭州——（商业新闻短讯）——杭州齐汉生物技术有限公司（“齐汉”或“齐汉生物技术”或“该公司”）是将多重基因组编辑技术应用于细胞疗法和器官移植的行业领导者，宣布了其开创性的研究，名为“测试多重抗ASFV CRISPR-Cas9在减少非洲猪瘟病毒中的作用”，这是美国微生物学会的学术期刊。

Qihan Biotech's R&D team led the study in collaboration with Professor Zezhong Zheng of South China Agricultural University, Professor Hongjiang Wei and Professor Hongye Zhao of Yunnan Agricultural University, and Professor George Church and his team at Harvard University..

奇翰生物技术的研发团队与华南农业大学郑泽中教授、云南农业大学魏洪江教授和赵洪业教授以及哈佛大学乔治·丘奇教授和他的团队合作领导了这项研究。。

The study indicates that the long-term expression of CRISPR-Cas, specifically targeting the pathogen genome in living organisms, holds promise as an effective method to inhibit the replication and infection of the African Swine Fever Virus (ASFV). The research team designed a CRISPR-Cas system to disrupt nine specific sites within the ASFV genome and observed a significant inhibitory effect on virus replication in vitro.

该研究表明，CRISPR-Cas的长期表达，特别是针对生物体中的病原体基因组，有望成为抑制非洲猪瘟病毒（ASFV）复制和感染的有效方法。该研究团队设计了一种CRISPR-Cas系统来破坏ASFV基因组内的9个特定位点，并观察到对体外病毒复制的显着抑制作用。

Subsequently, the team achieved stable insertion of CRISPR-Cas into pig cells through gene editing and produced pigs that continuously express CRISPR-Cas, targeting the ASFV genome using cloning technology. In live animal pathogen challenge experiments, the transgenic pigs demonstrated a certain level of resistance to African Swine Fever..

。在活体动物病原体攻击实验中，转基因猪对非洲猪瘟表现出一定程度的抗性。。

To our knowledge, this research marks the world's first successful creation of a large transgenic animal with stable CRISPR-Cas gene expression, enabling resistance to exogenous viral invasion through the specific multi-site cutting of the viral genome. African Swine Fever is a lethal disease with a long-term, massive impact on global agricultural livestock.

据我们所知，这项研究标志着世界上首次成功创建了具有稳定CRISPR-Cas基因表达的大型转基因动物，通过病毒基因组的特定多位点切割能够抵抗外源性病毒入侵。非洲猪瘟是一种致命疾病，对全球农业牲畜产生长期、巨大的影响。

This study assessed and enhanced pigs' resistance to African Swine Fever Virus (ASFV) infection, providing valuable insights for future antiviral immune strategies in agriculture and livestock farming. Furthermore, this research offers greater safety assurances for utilizing pigs as organ bioreactors in xenotransplantation..

这项研究评估并增强了猪对非洲猪瘟病毒（ASFV）感染的抵抗力，为农业和畜牧业未来的抗病毒免疫策略提供了有价值的见解。此外，这项研究为利用猪作为异种移植中的器官生物反应器提供了更大的安全保证。。

Dr. Luhan Yang, Founder and CEO of Qihan Biotech, stated, 'Qihan's vision is to develop off-the-shelf cellular and organ products to serve millions of patients. We focus on developing allogeneic cell therapies in the short term, yet we also have been committed to xenotransplantation research. Many scientific questions exist to explore and solve in addressing cell and organ rejection issues and controlling biosafety.

齐汉生物科技创始人兼首席执行官杨路汉博士表示，“齐汉的愿景是开发现成的细胞和器官产品，为数百万患者服务。我们专注于在短期内开发同种异体细胞疗法，但我们也致力于异种移植研究。在解决细胞和器官排斥问题以及控制生物安全方面，存在许多需要探索和解决的科学问题。

Through the solid collaboration of Qihan's team and our partners, I am confident we will steadily propel our projects forward and realize the company's vision.'.

通过齐汉团队和合作伙伴的紧密合作，我相信我们将稳步推进我们的项目，实现公司的愿景。”。

Original paper link: https://journals.asm.org/doi/10.1128/spectrum.02164-23

原始纸张链接：https://journals.asm.org/doi/10.1128/spectrum.02164-23

About Qihan Biotech

关于奇翰生物科技

Qihan Biotech is a biotechnology company applying genome editing technology to develop novel cell therapies and organs for transplantation. The company's mission is to use high-throughput, multiplexable genome editing combined with expertise in transplantation immunology to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, autoimmune diseases, organ failure, and other complex medical conditions.

齐汉生物科技是一家应用基因组编辑技术开发新型细胞疗法和器官移植的生物技术公司。该公司的使命是利用高通量、可多重扩增的基因组编辑技术，结合移植免疫学的专业知识，创建具有免疫特权的同种异体细胞和异种器官，用作治疗癌症、自身免疫性疾病、器官衰竭和其他复杂疾病的疗法。

With a vision to create a world in which cell and organ therapies are universally available to patients, Qihan Biotech has raised two financing rounds. It has multiple products at different stages of development, including QN-019a, which had already received IND approval from China NMPA to treat CD19-positive relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

齐汉生物科技公司（QihanBiotech）已经发起了两轮融资，旨在创造一个细胞和器官疗法普遍适用于患者的世界。它有多种处于不同开发阶段的产品，包括QN-019a，该产品已获得中国NMPA的IND批准，用于治疗CD19阳性复发/难治性侵袭性B细胞非霍奇金淋巴瘤。

Qihan's deep scientific experience and technology advancements have enabled the company to create cutting-edge cell therapy products. Qihan Biotech is headquartered in Hangzhou, China. For more information, please visit the company's website at www.qihanbio.com..

齐汉深厚的科学经验和技术进步使公司能够创造出尖端的细胞疗法产品。奇翰生物科技总部位于中国杭州。欲了解更多信息，请访问公司网站www.qihanbio.com。。

Forward-looking Statements

前瞻性声明

This release contains statements including, but not limited to, Qihan’s research development and/or relevant programs, its past, ongoing, and planned research studies, and the potential of Qihan’s research candidate. These and any other statements in this release are based on Qihan management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such statements.

本版本包含声明，包括但不限于齐汉的研究发展和/或相关计划，其过去，正在进行和计划进行的研究，以及齐汉研究候选人的潜力。本新闻稿中的这些和任何其他声明均基于齐汉管理层目前对未来事件的预期，并受到许多风险和不确定性的影响，这些风险和不确定性可能导致实际结果与此类声明中规定或暗示的结果产生重大不利影响。

These risks and uncertainties include, but are not limited to, the risk that Qihan’s research program may not warrant further development, the risk that results observed in prior studies of Qihan’s research candidates will not be observed in ongoing or future studies involving these candidates, the risk of a delay or difficulties in the developing or transforming of Qihan’s research candidates, the risk that Qihan may cease or delay the research development of any of its candidates for a variety of reasons.

这些风险和不确定性包括但不限于，齐汉的研究计划可能不值得进一步发展的风险，齐汉研究候选人先前研究中观察到的结果在涉及这些候选人的正在进行或未来研究中不会被观察到的风险，齐汉研究候选人发展或转化过程中出现延迟或困难的风险，齐汉可能因各种原因停止或延迟任何候选人的研究发展的风险。

Qihan is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in this release as a result of new information, future events, or otherwise. Information concerning therapies and related products contained herein is not intended as medical advice..

Qihan在本版本中提供截至该日期的信息，不承担因新信息、未来事件或其他原因而更新本版本中包含的任何声明的任何义务。此处包含的有关治疗和相关产品的信息不作为医疗建议。。

Source: Hangzhou Qihan Biotech Co., Ltd.

。